Nuvation Bio and Nu Holdings see analyst activity and growth momentum

Nuvation Bio (NYSE:NUVB) has received new coverage from JPMorgan Chase & Co., which initiated an “overweight” rating with a $13.00 price target. This target suggests a potential upside of approximately 99.69% from the company’s previous closing price. Other analysts have also recently updated their outlooks for the company, including HC Wainwright, which raised its price target to $21.00 with a “buy” rating, and Royal Bank of Canada, which increased its target to $20.00 with an “outperform” rating.

Separately, Nu Holdings Ltd. (NU) is showing growth momentum in the fintech sector, driven by customer expansion in Brazil, Mexico, and Colombia. Analysts note the company’s exceptional net income growth and operational efficiency, suggesting a potential swing long setup as the stock tests moving average support.